This Task Force report by the American College of Neuropsychopharmacology evaluates the safety & efficacy of selective serotonin reuptake inhibitor antidepressants for depressed youth under 18 years. The report was undertaken after regulatory agencies in the United States & the United Kingdom raised concerns in 2003 about the possibility that treatment of depression in children & adolescents with these drugs may increase the risk of suicide ideation or suicide attempts. 6 recommendations are made. (74 refs., 2 appendices)